induction of thymic lymphosarcoma and mammary adenocarcinomas in rats by oral administration of the antitumor agent, 4 (5)-(3,3-dimethyl-1-triazeno) imidazole-5 (4)-carboxamide.
D000230:Adenocarcinoma / Q000139:chemically induced* / Q000473:pathology; D002282:Adenocarcinoma, Bronchiolo-Alveolar / Q000139:chemically induced; D000284:Administration, Oral; D000818:Animals; D000831:Animals, Newborn; D001853:Bone Marrow; D001932:Brain Neoplasms / Q000139:chemically induced / Q000473:pathology; D002471:Cell Transformation, Neoplastic / Q000139:chemically induced; D004806:Ependymoma / Q000139:chemically induced / Q000473:pathology; D005260:Female; D007093:Imidazoles / Q000008:administration & dosage / Q000627:therapeutic use / Q000633:toxicity*; D008175:Lung Neoplasms / Q000139:chemically induced; D008198:Lymph Nodes; D008207:Lymphatic Metastasis / Q000473:pathology; D008228:Lymphoma, Non-Hodgkin / Q000139:chemically induced* / Q000473:pathology; D008325:Mammary Neoplasms, Experimental / Q000139:chemically induced* / Q000473:pathology; D051381:Rats; D012513:Sarcoma, Experimental / Q000139:chemically induced; D013160:Splenic Neoplasms / Q000139:chemically induced / Q000473:pathology; D013953:Thymus Neoplasms / Q000139:chemically induced* / Q000473:pathology
D007093:Imidazoles